Who Exports Moxifloxacin from India — 336 Suppliers Behind a $32.8M Market
India's moxifloxacin export market is supplied by 336 active exporters who collectively shipped $32.8M across 2,413 shipments. MACLEODS PHARMACEUTICALS LTD leads with a 44.9% market share, followed by MSN LABORATORIES PRIVATE LIMITED and EUGIA PHARMA SPECIALITIES LIMITED. The top 5 suppliers together control 70.1% of total export value, reflecting a concentrated market structure.
Top Moxifloxacin Exporters from India — Ranked by Export Value
MACLEODS PHARMACEUTICALS LTD is the leading moxifloxacin exporter from India, holding a 44.9% share of the $32.8M market across 2,413 shipments from 336 exporters. The top 5 suppliers — MACLEODS PHARMACEUTICALS LTD, MSN LABORATORIES PRIVATE LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, MICRO LABS LIMITED, AJANTA PHARMA LIMITED — collectively control 70.1% of total export value, indicating a highly concentrated market. Individual shares are: MACLEODS PHARMACEUTICALS LTD (44.9%), MSN LABORATORIES PRIVATE LIMITED (7.0%), EUGIA PHARMA SPECIALITIES LIMITED (7.0%), MICRO LABS LIMITED (7.0%), AJANTA PHARMA LIMITED (4.2%).
Top Moxifloxacin Exporters from India
Ranked by export value · 336 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MACLEODS PHARMACEUTICALS LTD MOXIFLOXACIN HYDROCHLORIDE 400 MG TABLETS.MOXIFLOXACIN HYDROCHLORIDE 400MG TABLETS.FLOXSAFE 400MGFCA +PFRC 10X10S | $14.7M | 14 | 44.9% |
| 2 | MSN LABORATORIES PRIVATE LIMITED MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% W/VMFLOX [MOXIFLOXACIN 0.5% W/V - 5ML]MOXIFLOXACIN HYDROCHLORIDE TABLETS 400MG | $2.3M | 13 | 7.0% |
| 3 | EUGIA PHARMA SPECIALITIES LIMITED MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% W/VMOXIFLOXACIN HYDROCHLORIDE TABLETS 400MGMOXIFLOXACIN HCL INJ 1.6MG/ML 12S US SU6 | $2.3M | 1 | 7.0% |
| 4 | MICRO LABS LIMITED MOXIFLOXACIN HYDROCHLORIDE 400 MG TABLETS.MOXIFLOXACIN HYDROCHLORIDE 400MG TABLETS.MFLOX [MOXIFLOXACIN 0.5% W/V - 5ML] | $2.3M | 14 | 7.0% |
| 5 | AJANTA PHARMA LIMITED MOXISWIFT(MOXIFLOXACIN INFUSION 400MG/10APDROPS EYE DROPS[MOXIFLOXACIN HYDROCHLOMOXIFLOXACIN TAB 400MG 7BL FR VIA | $1.4M | 11 | 4.2% |
| 6 | MYLAN LABORATORIES LIMITED MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% W/VMOXIFLOXACIN HYDROCHLORIDE TABLETS 400MGMOXIFLOXACIN HCL INJ 1.6MG/ML 12S US SU6 | $1.0M | 4 | 3.1% |
| 7 | AUROLAB TRUST MOXIFLOXACIN HYDROCHLORIDE 400 MG TABLETS.MOXIFLOXACIN HYDROCHLORIDE 400MG TABLETS.MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% W/V | $806.3K | 46 | 2.5% |
| 8 | ALEMBIC PHARMACEUTICALS LIMITED MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% W/VMOXIFLOXACIN HYDROCHLORIDE TABLETS 400MGMOXIFLOXACIN HCL INJ 1.6MG/ML 12S US SU6 | $683.8K | 1 | 2.1% |
| 9 | MACLEODS PHARMACEUTICALS LIMITED MOXIFLOXACIN HYDROCHLORIDE 400 MG TABLETS.MOXIFLOXACIN HYDROCHLORIDE 400MG TABLETS.FLOXSAFE 400MGFCA +PFRC 10X10S | $656.3K | 10 | 2.0% |
| 10 | MANKIND PHARMA LIMITED MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% W/VMOXIFLOXACIN HYDROCHLORIDE TABLETS 400MGMOXIFLOXACIN HCL INJ 1.6MG/ML 12S US SU6 | $452.0K | 2 | 1.4% |
| 11 | SUN PHARMACEUTICAL INDUSTRIES LIMITED MOXIFLOXACIN HYDROCHLORIDE 400 MG TABLETS.MOXIFLOXACIN HYDROCHLORIDE 400MG TABLETS.MICROMOX 400 (MOXIFLOXACIN 400MG TABLETS | $401.3K | 6 | 1.2% |
| 12 | AUROBINDO PHARMA LIMITED MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% W/VMOXIFLOXACIN HYDROCHLORIDE TABLETS 400MGMOXIFLOXACIN HCL INJ 1.6MG/ML 12S US SU6 | $353.8K | 1 | 1.1% |
| 13 | HETERO LABS LIMITED MOXIFLOXACIN 400MG TABLETSMIFLOKO-DELTA 0.5%W/V&0.1%W/V 5ML | $260.9K | 3 | 0.8% |
| 14 | INDOCO REMEDIES LIMITED MOXIFLOXACIN TAB 400MG 7BL FR VIA | $239.8K | 8 | 0.7% |
| 15 | ALVITA PHARMA PRIVATE LIMITED | $235.8K | 1 | 0.7% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Moxifloxacin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| MACLEODS PHARMACEUTICALS LIMITED | Approved | Yes | Yes | 1 | FDA approval and WHO-GMP certification confirmed. |
| MSN LABORATORIES PRIVATE LIMITED | Approved | Yes | Yes | 1 | FDA approval and WHO-GMP certification confirmed. |
| EUGIA PHARMA SPECIALITIES LIMITED | Approved | Yes | Yes | 1 | FDA approval and WHO-GMP certification confirmed. |
| MICRO LABS LIMITED | Approved | Yes | Yes | 2 | FDA approval and WHO-GMP certification confirmed. |
| AJANTA PHARMA LIMITED | Approved | Yes | Yes | 1 | FDA approval and WHO-GMP certification confirmed. |
| MYLAN LABORATORIES LIMITED | Approved | Yes | Yes | 1 | FDA approval and WHO-GMP certification confirmed. |
| ALEMBIC PHARMACEUTICALS LIMITED | Approved | Yes | Yes | 5 | FDA approval and WHO-GMP certification confirmed. |
| AUROBINDO PHARMA LIMITED | Approved | Yes | Yes | 11 | FDA approval and WHO-GMP certification confirmed. |
| HETERO LABS LIMITED | Approved | Yes | Yes | 4 | FDA approval and WHO-GMP certification confirmed. |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Yes | 9 | FDA approval and WHO-GMP certification confirmed. |
TransData Nexus reviewed the regulatory standing of 10 leading Moxifloxacin exporters from India. 10 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 10 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Moxifloxacin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city's pharmaceutical landscape is characterized by numerous manufacturers specializing in APIs, including Moxifloxacin. Companies such as Manus Aktteva Biopharma LLP, an ISO 9001:2015 certified global supplier, offer Moxifloxacin APIs sourced from GMP and USFDA approved units. This concentration of API manufacturers positions Hyderabad as a pivotal hub for sourcing high-quality bulk drugs.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a prominent center for pharmaceutical formulations. This region hosts numerous companies that manufacture and export finished dosage forms of Moxifloxacin. For instance, Euro Head Infusion, based in Ahmedabad, produces Moxifloxacin Infusion adhering to WHO-GMP and EU-GMP standards, ensuring compliance with international quality norms. The presence of such certified manufacturers underscores the region's significance in the production of high-quality pharmaceutical formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products, including Moxifloxacin. The region's well-developed port infrastructure facilitates efficient international distribution. Export data indicates that significant quantities of Moxifloxacin are shipped from ports like Nhava Sheva (Jawaharlal Nehru Port) in Mumbai to various global destinations. This strategic location enhances the export capabilities of pharmaceutical companies operating in the area.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is recognized for its favorable tax incentives, attracting numerous pharmaceutical manufacturers. Companies in this region produce a range of pharmaceutical products, including Moxifloxacin tablets. For example, Associated Biotech, located in Baddi, manufactures Moxifloxacin 400 mg tablets, adhering to WHO-GMP standards. The tax benefits and established manufacturing facilities make this region a competitive player in the pharmaceutical industry.
5Sourcing Recommendations
- Evaluate Supplier Certifications: Prioritize suppliers with WHO-GMP, EU-GMP, and ISO certifications to ensure compliance with international quality standards.
- Assess Export Capabilities: Consider suppliers with established export records and efficient logistics, particularly those utilizing major ports like Nhava Sheva for global distribution.
- Analyze Product Range: Select suppliers offering a comprehensive range of Moxifloxacin products, including APIs and finished formulations, to streamline procurement processes.
- Review Regulatory Compliance: Ensure suppliers provide complete regulatory documentation, such as Drug Master Files (DMFs) and Certificates of Analysis (CoAs), to facilitate smooth market entry and compliance.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Moxifloxacin exporters from India
EUGIA PHARMA SPECIALITIES LIMITED — US FDA inspection results in four observations
The US Food and Drug Administration (FDA) conducted an inspection at Eugia Pharma Specialities Ltd's Unit-1 formulation manufacturing facility in Telangana from February 16 to 27, 2026, resulting in four observations. - IMPACT: Potential delays in Moxifloxacin production and export due to regulatory compliance measures.
Impact: Potential delays in Moxifloxacin production and export due to regulatory compliance measures.
MACLEODS PHARMACEUTICALS LTD — Trademark dispute with Alkem Laboratories Ltd.
Macleods Pharmaceuticals Ltd. filed a lawsuit against Alkem Laboratories Ltd. regarding the use of the trademark 'ALSITA,' alleging similarity to its own 'ALRISTA' brand. The case was heard in the Delhi High Court. - IMPACT: No direct impact on Moxifloxacin exports; however, legal proceedings may divert resources.
Impact: No direct impact on Moxifloxacin exports; however, legal proceedings may divert resources.
AJANTA PHARMA LIMITED — Tentative ANDA approval for Tofacitinib tablets
Ajanta Pharma received tentative approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Tofacitinib tablets, 10 mg, used in treating rheumatoid arthritis. - IMPACT: Diversification of product portfolio may enhance overall export capabilities, indirectly benefiting Moxifloxacin exports.
Impact: Diversification of product portfolio may enhance overall export capabilities, indirectly benefiting Moxifloxacin exports.
Common Questions — Moxifloxacin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which moxifloxacin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MACLEODS PHARMACEUTICALS LTD leads with 27 recorded shipments worth $14.7M. MSN LABORATORIES PRIVATE LIMITED (89 shipments) and EUGIA PHARMA SPECIALITIES LIMITED (39 shipments) are also established high-volume exporters.
Q How many moxifloxacin manufacturers are there in India?
India has 336 active moxifloxacin exporters with a combined export market of $32.8M across 2,413 shipments to 137 countries. The top 5 suppliers hold 70.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for moxifloxacin from India?
Average FOB unit price: $7.12 per unit, ranging from $0.00 to $383.19. Average shipment value: $13.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 336 verified Indian exporters of Moxifloxacin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,413 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 137 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,413 Verified Shipments
336 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists